# reload+after+2024-01-21 19:45:39.677170
address1§Clarendon House
address2§2 Church Street
city§Hamilton
zip§HM 11
country§Bermuda
website§https://www.kiniksa.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
fullTimeEmployees§220
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Sanj K. Patel', 'age': 53, 'title': 'CEO & Chairman of the Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 1444526, 'exercisedValue': 0, 'unexercisedValue': 9860411}, {'maxAge': 1, 'name': 'Mr. Eben  Tessari', 'age': 41, 'title': 'Senior VP & COO', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 643751, 'exercisedValue': 0, 'unexercisedValue': 1625321}, {'maxAge': 1, 'name': 'Dr. John F. Paolini', 'age': 58, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 753702, 'exercisedValue': 0, 'unexercisedValue': 3678576}, {'maxAge': 1, 'name': 'Mr. Mark  Ragosa C.F.A.', 'age': 48, 'title': 'Senior VP & CFO', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael R. Megna CPA', 'age': 52, 'title': 'Chief Accounting Officer & Group VP of Finance', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mei  Jang', 'title': 'Senior VP of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Rachel  Frank', 'title': 'Associate Director of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Chad  Morin', 'title': 'SVP, Chief Compliance Officer & Head of Quality', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Madelyn  Zeylikman', 'title': 'SVP, General Counsel & Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melissa  Manno', 'title': 'Senior VP & Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§8
compensationRisk§8
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.076
priceToSalesTrailing12Months§5.177513
currency§USD
dateShortInterest§1702598400
forwardEps§-0.31
pegRatio§0.52
exchange§NMS
quoteType§EQUITY
shortName§Kiniksa Pharmaceuticals, Ltd.
longName§Kiniksa Pharmaceuticals, Ltd.
firstTradeDateEpochUtc§1527255000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7ea20e71-749b-31b8-994b-79f75933ead7
gmtOffSetMilliseconds§-18000000
targetHighPrice§32.0
targetLowPrice§23.0
targetMeanPrice§27.2
targetMedianPrice§28.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§3.818
grossMargins§0.68788004
ebitdaMargins§-0.06765
trailingPegRatio§None
